SUPNNasdaqPharmaceutical PreparationsFiscal year ends December 31
SUPERNUS PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$39.84+1.96 (+5.17%)
Close on Oct 19, 2026
- Market cap
- $2.31B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$10.33 (−20.59%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
SUPERNUS PHARMACEUTICALS, INC. grew revenue 24.9% to $830.44M over the twelve months to Jun 30, 2026. Operating income fell 303.4% to -$130.46M, moving the operating margin from 9.6% to -15.7%. Free cash flow was $18.79M, down 89.9% from a year earlier.
Revenue
$830.44M
+24.9% vs. a year earlier
Operating income
-$130.46M
-303.4% vs. a year earlier
Free cash flow
$18.79M
-89.9% vs. a year earlier
EPS, diluted
-$1.92
-267.0% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.31B
- P/E ratio
- –
- Price to sales
- 2.79
- Price to book
- 2.24
- Dividend yield
- –
- Free cash flow yield
- 0.81%
Fundamentals
- Revenue
- $830.44M
- Net income
- -$109.89M
- EPS, diluted
- -$1.92
- Free cash flow
- $18.79M
- Book value per share
- $17.76
- Diluted shares
- 58M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$830.44M+24.9% YoY
Gross profit
$731.41M+24.2% YoY
Operating income
-$130.46M-303.4% YoY
Net income
-$109.89M-270.4% YoY
EPS, diluted
-$1.92-267.0% YoY
Free cash flow
$18.79M-89.9% YoY
Reported periodTrailing twelve months